Clinical efficacy and pharmacoeconomics of tofacitinib combined with methotrexate for rheumatoid arthritis
Objective To evaluate the clinical efficacy and cost-effectiveness of tofacitinib combined with methotrexate for rheumatoid arthritis(RA).Methods A retrospective analysis was conducted on 100 patients with RA admitted to our hospital from January 2022 to December 2023.They were randomly divided into a control group and an observation group,50 patients in each group.The control group was treated with iguratimod combined with methotrexate,while the observation group was treated with tofacitinib combined with methotrexate.Both groups were treated for 12 weeks.The clinical efficacy and the adverse reactions were compared between both groups.Symptom changes(swollen joints,tender joints,and morning stiffness duration),C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),routine blood test and liver and kidney function were observed before and after the treatment.Cost-effectiveness analysis and sensitivity analysis were conducted.Results After the treatment,the total effective rates of both the control group and the observation group were 86.00％(43/50)and 90.00％(45/50),without significant difference(P＞0.05).Compared with the pre-treatment period,both groups showed a significant decrease in the number of swollen joints,tender joints,morning stiffness duration,CRP and ESR(P＜0.05),but no significant difference(P＞0.05).After the treatment,there was no significant difference in the overall incidence of adverse reactions in both groups(P＞0.05).The cost-effectiveness analysis showed that the treatment cost for the control group and the observation group were 2283.36 yuan and 860.40 yuan,respectively,indicating lower cost and better pharmacoeconomic performance in the observation group.The consistency between the sensitivity analysis and the cost-effectiveness analysis indicated reliability of this study.Conclusion Either tofacitinib or iguratimod,when combined with methotrexate,has better therapeutic effect and improves clinical symptoms in the treatment of RA.Tofacitinib with methotrexate is more cost-effective.
万方数据
维普
